Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform designed to deliver RNA payloads, such as mRNA, capable of engineering specific cell...
Related Questions
How will AbbVie’s acquisition of Capstan Therapeutics affect ABBV’s short‑term stock volatility and price target?
What are the projected revenue and margin contributions from the tLNP anti‑CD19 CAR‑T platform, and how does this compare to AbbVie’s existing pipeline and peers in the immunotherapy space?
What regulatory, clinical‑trial, and integration milestones are expected for the tLNP platform, and what risks could delay or impact the anticipated upside?